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IntroductIon
Enteropathy-associated T cell lymphoma (EATL) is an un-
common but lethal type of peripheral T cell lymphoma that 
appears to be rising in incidence (Swerdlow et al., 2008; 
Sharaiha et al., 2012). EATL is the most common oncologic 
complication of celiac disease, with a prevalence of ∼1% in 
those patients (Ferreri et al., 2011). The role of genetic muta-
tions in the pathogenesis of EATL is largely unknown.
Past World Health Organization lymphoma classifica-
tion systems (Swerdlow et al., 2008; Campo et al., 2011) have 
recognized two subtypes of EATL. Type I EATL has a more 
variable histology, is more prevalent in Northern Europe 
(Delabie et al., 2011), and is strongly associated with celiac 
disease. Type II EATL has a more uniform histology, occa-
sional association with celiac disease (Delabie et al., 2011), 
and is more prevalent in Asia (Sun et al., 2011; Tse et al., 2012; 
Kikuma et al., 2014). The diagnostic distinction between 
these two types is not always clear. Cases are currently classi-
fied based on their morphology and immunophenotype, with 
both types sharing common T cell markers but type II cases 
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expressing CD56 more frequently (Delabie et al., 2011; Arps 
and Smith, 2013). Most type I patients carry the celiac dis-
ease–associated HLA genotype DQA1*0501, DQB1*0201, 
whereas that genotype occurs at a frequency similar to the 
general population in type II patients. Based on these distinc-
tions, it has been recommended that type II EATL should 
be reclassified as a distinct entity, known as monomorphic 
epitheliotropic intestinal T cell lymphoma (Swerdlow et al., 
2016). The genomic distinction between the two described 
types of EATL is not well understood. Compared with other 
peripheral T cell lymphomas, which are primarily derived 
from αβ T cells, both types of EATL frequently arise from γδ 
T cells, a feature they share with hepatosplenic T cell lym-
phoma (HSTL; Belhadj et al., 2003).
In this study, we applied whole-exome and transcriptome 
sequencing to define novel driver mutations, copy-number al-
terations, and expression patterns in both types of EATL. We 
found that both types of EATL are characterized by frequent 
silencing mutations in SETD2. We further modeled the effects 
of SETD2 loss in vivo by developing a T cell–specific knock-
out of the gene in mice. We found that mice with Setd2 loss 
manifested an expansion of γδ T cells, suggesting novel roles 
for SETD2 in T cell development. Together, our data render 
the most comprehensive genetic portrait yet of EATL and may 
inform future classification schemes of this disease.
rESuLtS
Whole-exome sequencing defines driver mutations and 
copy-number alterations in EAtL
We performed whole-exome sequencing on 69 EATL tu-
mors along with paired normal samples when available (n 
= 36), for a total of 105 exomes. Mean exome sequencing 
depth was greater than 70×. EATL cases were separated into 
the 36 cases with paired normal tissue available, deemed the 
“discovery set,” and the remaining samples, a “validation set.”
Fig. 1  a shows the mutation status of each significant 
EATL driver gene in each EATL case, with the number of 
cases summarized in the bar graphs of Fig. 1 b. Every gene 
shown had at least two confirmed somatic mutations in the 
discovery set with additional rare variants in the validation set 
that were comparable to those in the discovery set in terms 
of their frequency in the general population, distribution of 
amino acid alterations, location in protein domains, and evo-
lutionary conservation, as we have described previously (Love 
et al., 2012; Zhang et al., 2014).
The most frequently mutated gene in EATL was found 
to be SETD2 (32% of cases), with the mutations featuring a 
large proportion (41%) of loss-of-function frameshift indels 
or nonsense mutations. Other chromatin modifiers were also 
mutated in a significant number of cases, such as TET2 and 
YLPM1, and typically exhibit loss-of-function type mutations.
The JAK-STAT pathway was the most commonly mu-
tated signaling pathway, with frequent activating mutations 
in STAT5B (29%), followed by JAK1 (23%), JAK3 (23%), 
STAT3 (16%), and frameshift mutations in the negative reg-
ulator of the pathway, SOCS1 (7%). Interestingly, the RAS 
family of genes, which are rarely mutated in lymphomas, 
were also implicated in several EATL cases, with mutations at 
known activating hotspots (G12/G13) in NRAS and KRAS.
DNA damage response and repair genes were fre-
quently mutated in EATL. TP53 was mutated in 10% of the 
cases. Other DNA damage–related genes mutated include 
BCL11B, a known tumor suppressor in T cell lymphomas, 
and BRIP1, a DNA helicase known to be involved in the 
repair of double-strand breaks.
Other noteworthy genes mutated in EATL included 
apoptosis-associated DAPK3 (10%), the cell cycle transcrip-
tion factor BBX (16%), the interferon-related transcription 
factor PRDM1 (9%), and the telomerase reverse transcription 
TERT (17%). Full details of somatic mutations detected in 
EATL cases are described in Table S1.
We analyzed the mutual exclusion patterns of the mutated 
driver genes using the weighted row exclusivity test (Leiserson 
et al., 2016). Examining sets of 3 genes, we found 11 significant 
sets, involving 12 different genes, which are listed in Table S2. 
The JAK-STAT pathway is prominent among the mutually 
exclusive genes, with all of the significant sets including at least 
one of the genes from STAT5B, STAT3, JAK1, and JAK3, as 
shown in Fig. S1 a. We also quantified how often each gene pair 
occurs among the significant sets of four genes, which showed 
PRDM1 and DAPK3, followed by STAT3 and STAT5B, as 
the most common mutually exclusive gene pairs (Fig. S1 b).
To further understand the genetic drivers of EATL, we 
investigated the distribution of allele frequencies of mutations 
in the driver genes and the fraction of mutations that appear to 
be clonal. Estimates of cancer cell fraction based on observed 
allele frequencies for each driver gene are shown in Fig. S1 
(c and d). STK10, DAPK3, TP53, and STAT5B showed the 
highest proportion of clonal events among the driver genes.
We next examined copy-number alterations in these 
cases. Interestingly, most of the copy-number alterations in 
EATL cases occurred in very large regions, frequently com-
prising an entire arm of the chromosome. After correcting for 
these effects, there were no focal gene-level alterations that 
reached statistical significance.
Fig. 1 c depicts the significant copy number alteration 
status of each EATL case by chromosomal arm. Similar to 
previous studies investigating both type I and type II EATLs 
(deLeeuw et al., 2007; Ko et al., 2010; Tomita et al., 2015), we 
observed amplifications in chromosome 9q to be the most 
common in EATL (46%). We also noted gains in chromo-
somes 1q, 7q, and 8q, as well as losses in 8p, which were each 
present in 20–30% of cases. Many cases had more than one 
of the noted alterations. The total number of events per case 
out of the shown EATL driver events is depicted in Fig. 1 d. 
Additional details of copy-number alterations are in Table S3.
clinical features of the EAtL cohort
Median overall survival was 10 mo, with a 27% 2-yr survival 
rate (Fig. 1 e), highlighting the dismal prognosis in these pa-
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Figure 1. Somatic mutations, copy-number alterations, and survival of EAtL patients. (a) Heat map of mutations in EATL cohort (n = 69). Every 
box represents the mutation status of a patient for a particular gene. Columns are split into discovery set with paired normals (n = 36) and validation set 
(n = 33). Gray, no mutation; teal, synonymous SNV; pink, in-frame indel; purple, missense SNV; green, frameshift indel; orange, nonsense SNV. Black dots 
indicate more than one mutation in that gene/patient, with boxes split diagonally to show different functions of multiple mutations. (b) Bar graph showing 
the percentage of cases in the cohort affected by each mutated gene. Bars are color coded by the most-damaging event type observed in each patient. 
(c) Heat map of arm-level copy-number alterations for each patient (n = 69). Light blue, chr1q gain; dark blue, chr7q gain; light red, chr8p loss; dark red, 
chr8q gain; dark green, chr9q gain. (d) Bar graph showing number of events from mutated genes and copy-number alterations shown in the heat maps 
above (n = 69). Bars are color-coded based on the type of alteration. (e) Kaplan-Meier curve showing overall survival of the EATL cohort (n = 55 with avail-
able outcome data). Median survival is 10 mo; 1-yr survival rate is 44%.
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tients. Good performance status (P = 0.003), low stage (P = 
0.006), and complete response to initial treatment (P < 0.001) 
were all associated with better outcome (Fig. S1, e–g).
Assignment of each case to the two types of EATL was 
determined based on World Health Organization criteria 
(Swerdlow et al., 2008). The two types of EATL were re-
markably similar in terms of overall survival (median survival: 
9 mo for type I, 11 mo for type II; Fig. S1 h), age of onset (64 
yr for type I, 59 yr for type II), and gender (44% male for type 
I, 52% male for type II). As expected, the type I patients were 
primarily Caucasian (93%), whereas the type II patients were 
split (57% Caucasian and 39% Asian).
History or concurrent diagnosis of celiac disease was 
observed in 84% of type I EATL cases compared with 16% 
of type II cases. The DQ2 or DQ8 HLA genotypes were ob-
served in 88% of type I EATL patients, and 43% of type II 
EATL patients (Table S4). Among patients with type I EATL, 
adherence to a gluten-free diet appeared to correlate with 
improved outcomes (P = 0.07; Fig. S1 i).
Additional clinical parameters are summarized in 
Table 1, with full clinical and pathological details in Table S5.
Genomic and transcriptomic differences between 
type I and type II EAtL
Given the paucity of our understanding of the molecular dis-
tinction between the two described types of EATL, we fur-
ther investigated the mutation frequencies in type I (n = 41) 
and type II (n = 23) EATLs (Fig. 2 a). Overall, we found that 
the overwhelming majority of the genes (90%) to be mutated 
in both types of EATL. A few selected genes appeared to be 
mutated more frequently in one type or the other. SOCS1 
and DAPK3 had higher frequencies in type I, whereas KRAS, 
STAT5B (>50% in type II), and SETD2 (>60% in type II) 
had higher frequencies in type II EATL. Fig. 2 b shows simi-
lar findings when we examined copy-number alterations sep-
arately in type I and II cases. Chromosome 9q gains were the 
most common alteration in both types. Diagnostic guidelines 
have attributed 1q gains primarily to type I EATL (Arps and 
Smith, 2013); however, we found chromosome 1q gains to 
be present in at least 20% of cases in both types of EATL. 
Chromosome 8 alterations, particularly gains in chromosome 
8q, which includes MYC, were significantly more frequent in 
type II EATL but also occurred in type I.
These data indicate that type I and type II EATL cases 
have strongly overlapping genetic alterations and likely arise 
from shared genetic mechanisms.
We further investigated the gene expression profiles 
through transcriptome sequencing of 29 EATL tumors for 
which RNA was available, including type I (n = 16) and type 
II (n = 13) cases. Unbiased principal-component analysis re-
vealed that a large amount of variation in the gene expression 
data are driven by the differences between type I and type 
II cases. Plotting each of the EATL samples in the principal 
component space (Fig. 2 c) shows that the majority of sam-
ples segregate into the two groups corresponding essentially 
to the EATL subtypes, indicating robust differences in gene 
expression levels between the two subtypes. Based on these 
findings, we performed supervised differential expression 
analysis using the clinically derived labels of type I and type II. 
Fig. 2 d shows the genes that were at least 1.5-fold differen-
tially expressed between the two types, with a false discovery 
rate of less than 0.1. Some notable genes with higher ex-
pression in the type I cases, compared with type II, included 
STAT3, STAT5A, IRF1, and IRF4. The genes FAS LG, SYK, 
and TGBR1 were found to be more highly expressed in type 
II EATL than in type I. Transglutaminase 2 (TGM2) is an im-
portant enzyme and autoantigen in celiac disease (Dieterich 
et al., 1997), which we found to be expressed at higher levels 
in the type I cases than in type II cases. NCAM1, also known 
as CD56, was expressed higher in type II EATL, consistent 
with the use of CD56 staining as a diagnostic feature of type 
II EATL. We did not find MYC to be differentially expressed, 
despite the higher proportion of chromosome 8q amplifica-
tions in type II. The full list of differentially expressed genes 
is included in Table S6.
Fig. 2 e depicts the heat map of the differentially ex-
pressed genes in the 29 EATL samples, along with HLA 
genotype and celiac disease status. With a false discovery rate 
(FDR) <0.1 and a fold change of at least 1.5× in either direc-
tion, 380 genes are higher in type II and 198 genes are higher 
in type I. The cluster assignment, based on consensus K-means 
clustering of the differentially expressed genes, was found to 
track very closely with the original clinical EATL subtype.
Gene set enrichment of the differentially expressed 
genes revealed significant overexpression of the interferon-γ 
signaling pathway (P < 0.001; Fig. 2, f and g) in type I EATLs. 
Genes expressed higher in type II EATL were found to be 
enriched for the natural killer-like cytotoxicity pathway (P 
= 0.02; Fig. 2, h and i). Both interferon-γ signaling and nat-
ural killer–like cytotoxicity (Meresse et al., 2006) are known 
functions of intraepithelial lymphocytes (IELs), which are the 
presumed cell of origin for EATLs (Ebert, 1990; Taguchi et 
al., 1991; Ishikawa et al., 1993; Kagnoff, 1998; Corazza et al., 
2000). Increased interferon-γ production has been described 
in patients with untreated celiac disease, consistent with the 
higher expression of this function in celiac-associated type I 
EATL (Kagnoff, 1998; Nilsen et al., 1998). Other enriched 
gene sets of interest included MAPK signaling, up-regulated 
in type II, consistent with a previous study of high MAPK 
protein expression in type II (Kikuma et al., 2014).
Thus, the two EATL types are characterized by highly 
overlapping genetic alterations, as well as robust differ-
ences in gene expression.
To further investigate the profiles of the EATL tumors, 
we compared the gene expression of the EATL samples to 
published data on purified T cell subsets in mouse (Heng et 
al., 2008). When ranking the T cell samples by mean cor-
relation to the EATL tumors, we find that the top ranked 
T cell subsets with most similarity to EATL samples include 
primarily γδ T cells (16/20), particularly activated IEL sam-
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Table 1. Summary of EAtL clinical characteristics
Parameter All EATL (n = 63) Type I (n = 41) Type II (n = 23)
Number (percentage) of cases
Sex
Male 33 (48) 18 (44) 12 (52)
Female 36 (52) 23 (56) 11 (48)
race
African-American 2 (3) 1 (2) 1 (4)
Caucasian 56 (81) 38 (93) 13 (57)
Asian 10 (14) 1 (2) 9 (39)
Age at diagnosis (yr)
Median (range) 62.0 (36.0–92.0) 64.0 (36–92) 59.0 (39.0–89.0)
celiac disease
Yes 35 (61) 32 (84) 3 (16)
Adherence to gluten-free diet
Yes 15 (36) 15 (44) 0 (0)
HLA type
DQ2/DQ8 49 (71) 36 (88) 10 (43)
tumor location
Small intestine 61 (93) 40 (97) 20 (91)
Size of tumor (cm)
Median (range) 7.0 (1.5–75.0) 8.0 (1.5–75.0) 6.0 (2.0–23.0)
Histopathology
CD3+ 57 (85) 30 (75) 23 (100)
CD4− 50 (91) 29 (91) 18 (95)
CD8+ 31 (46) 15 (37) 15 (68)
CD56+ 19 (33) 2 (5) 17 (85)
t cell receptor
AB 16 (46) 12 (43) 4 (57)
GD 9 (26) 6 (21) 3 (43)
EcoG performance score
0–1 20 (48) 14 (50) 6 (43)
2–4 22 (52) 14 (50 8 (57)
Ann Arbor stage
I 17 (40) 10 (36) 7 (47)
II 18 (42) 14 (50) 4 (27)
III–IV 8 (19) 4 (14) 4 (27)
High LdH
High LDH 31 (89) 21 (88) 10 (91)
B symptoms
Yes 27 (59) 19 (63) 7 (47)
Small bowel perforation
Yes 33 (57) 22 (58) 11 (55)
number of nodal sites
0 23 (48) 14 (48) 9 (56)
1 or more 15 (52) 15 (52) 7 (44)
Bone marrow involvement
No 32 (89) 20 (91) 12 (92)
treatment type
Curative 32 (64) 19 (58) 12 (75)
Minimal 18 (36) 14 (42) 4 (25)
response to initial treatment
CR 22 (63) 15 (71) 7 (50)
PR 5 (14) 3 (14) 2 (14)
NR 8 (23) 3 (14) 5 (36)
Progression or relapse
No 8 (24) 6 (32) 2 (14)
Yes 25 (76) 13 (68) 12 (86)
Survival
Median overall survival 10 mo 9 mo 11 mo
1-yr survival rate 44% 41% 50%
2-yr survival rate 27% 31% 19%
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Figure 2. differences between type I and type II EAtL: mutations, copy number, and gene expression. (a) Bar graph indicating frequency of muta-
tion of each gene within the type I (n = 41) and type II (n = 23) EATL cohorts separately: type I frequency (purple; left); type II frequency (orange; right). (b) 
Bar graph indicating frequency of alteration of each arm-level copy-number alteration within the type I (n = 41) and type II (n = 23) EATL cohorts separately: 
type I frequency (purple; left); type II frequency (orange; right). (c) Principal-component (PC) analysis of EATL RNA-sequencing gene expression data (n = 
29). The second principal component is on the x axis, and the third principal component is on the y-axis. One point is plotted for each sample in the analysis 
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ples. However, we did not find significant evidence within 
this dataset for T cell subsets that specifically resembled either 
type I or type II EATLs. More specific profiling data will be 
needed in future studies to fully answer the question of pre-
cise cell of origin for these EATL subtypes.
SEtd2 is frequently mutated in EAtL and plays a role in t 
cell development in vivo
Our mutation analysis in EATL tumors showed the histone 
lysine methyltransferase SETD2 to be the most frequently 
mutated gene in the disease (22 of 69 cases). The recurrent 
nonsense mutations and frameshift insertions and deletions 
(41% of SETD2 mutated cases) suggest that the role of mu-
tations in this gene in EATL is likely to be loss of function. 
Further, nine EATL cases had multiple mutations in SETD2, 
further supporting its role as a tumor suppressor in EATL. 
SETD2 has also been implicated as a driver gene with 
loss-of-function mutations in other malignancies, including 
clear cell renal carcinoma (Dalgliesh et al., 2010), DLB CL 
(Zhang et al., 2013), and acute leukemia (Zhu et al., 2014).
SETD2 is a histone lysine methyltransferase responsible 
for trimethylation of lysine 36 on histone 3 (H3K36me3), 
which is an epigenetic marker for active transcription. Its 
interactions with RNA polymerase II during transcription 
occur through the SRI domain (Kizer et al., 2005).
The distribution of mutations in SETD2 in our EATL 
cases is shown in Fig. 3 a (top). In a separate study examining 
the genetics of HSTL, a PTCL that arises predominantly from 
γδ T cells (McKinney et al., 2017), we also found SETD2 to 
be the most frequently silenced gene. For comparison, the 
distribution of mutations that we found in HSTL (McKin-
ney et al., 2017) are also shown in Fig.  3  a (bottom). This 
distribution of mutations in both lymphomas appears similar. 
SETD2 mutations in EATL were found to cluster within the 
SET domain, responsible for the methyltransferase activity 
of SETD2. In both EATL and HSTL, mutations cluster in 
the SRI domain, responsible for the interaction with RNA 
polymerase II. Both the SET and SRI domains have highly 
conserved amino acid sequences, as shown in Fig. 3 a. The 
missense mutations in SETD2 may thus to serve to effec-
tively disrupt the essential functions of SETD2 by altering 
these protein domains.
Given that both HSTLs and EATLs arise disproportion-
ately from γδ T cells and that γδ T cell expansion has been re-
ported in patients with untreated celiac disease (Kagnoff, 1998; 
Nilsen et al., 1998), we further investigated a potential role 
for SETD2 in T cell development. We began by examining 
gene expression patterns throughout the mouse T cell lineage 
from early T cell precursors to early double negative (DN) to 
double positive (DP) and finally to the αβ or γδ T cell subsets 
(Heng et al., 2008; Fig. 3 b). The decision checkpoint for the 
αβ versus γδ split occurs at the DN3 stage (Carpenter and 
Bosselut, 2010; Kreslavsky et al., 2010). We found that Setd2 is 
selectively up-regulated during the transition from early DN 
to DP T cells. Setd2 expression is then down-regulated by DP 
CD69pos T cells on their way to becoming αβ T cells. These 
results indicate that Setd2 up-regulation in the immature DP 
CD69neg stages is a critical step in confirming the αβ T cell 
lineage choice, and we hypothesized that the absence of Setd2 
up-regulation might favor the development of γδ T cells.
We further investigated the in vivo role of SETD2 in 
T cell development by breeding Setd2 conditional knockout 
mice with Lck-Cre transgenic mice, in which expression of 
Cre is restricted to the T cell lineage (Pan et al., 2002). The 
breeding scheme led to progeny whose T cells were either 
Setd2 wild-type, heterozygous, or deleted (Fig. 3 c shows the 
final cross and the mice selected for analysis). We then com-
pared T cell populations in young adult mice whose T cells 
were either wild-type or deleted for Setd2.
We first confirmed the loss of SETD2 protein in T 
cells from Setd2fl/fl;Lck-Cre+ mice. Protein lysates were 
made from splenic CD3epos T cells and analyzed by immu-
noblot. As shown in Fig. 3 d, there is a significant reduction 
in SETD2 protein in T cells isolated from Setd2fl/fl;Lck-Cre+ 
mice compared with Setd2+/+;Lck-Cre+ mice. We also ob-
served a corresponding decrease in H3K36me3, indicating 
a reduction of the histone methyltransferase activity in T 
cells lacking SETD2 protein.
We then assessed the effect of Setd2 loss upon T cell 
populations by dissecting IELs and gut-associated lymphoid 
in the principal-component space, labeled by the clinical assignment of type I or type II. (d) Volcano plot showing the selection of differentially expressed 
genes between EATL type I (n = 16) and type II (n = 13). Every point is one gene in the analysis (number of significant genes is 578). The x axis shows the 
log2 transformed ratio of mean expression in the type I samples over the mean expression in the type II samples. The y axis shows the log10 transformed 
q-value (after Benjamini–Hochberg correction) of a Student’s t test between EATL type I and type II. Genes that pass the thresholds for significance (dotted 
lines) are colored in orange and purple (FDR <0.1 and fold change >1.5× in either direction). Notable genes are labeled with text. (e) Heat map showing the 
genes that are differentially expressed between EATL type I and type II (type I: n = 16; type II: n = 13; number of genes shown is 578). Genes are median 
centered per row. Red indicates higher expression; blue indicates lower expression. The color bar shows the twofold range of expression depicted. Genes 
shown have FDR <0.1 and fold change >1.5× in either direction. Bars above the heat map indicate the clinical subtype, HLA type, and history of celiac 
disease. (f) Differentially expressed genes in the interferon-γ signaling pathway, showing higher expression in the EATL type I samples (type I: n = 16; type 
II: n = 13). (g) Gene set enrichment plot showing the enrichment of interferon-γ genes at the top of the ranked list, with genes ordered by difference in 
type I versus type II (type I: n = 16; type II: n = 13). Gene set enrichment analysis KS-test FDR <0.001. (h) Differentially expressed genes in the natural killer 
(NK)–like cytotoxicity pathway, showing higher expression in the EATL type II samples (type I: n = 16; type II: n = 13). (i) Gene set enrichment plot showing 
the enrichment of natural killer–like cytotoxicity genes at the top of the ranked list, with genes ordered by difference in type II versus type I (type I: n = 16; 
type II: n = 13). Gene set enrichment analysis KS-test FDR = 0.02.
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Figure 3. SEtd2 as a driver of increased γδ t cell proliferation. (a) Stem plot showing distribution of mutations in SETD2. (Top) Mutations in EATL (n 
= 69). (Middle) Mutations in HSTL, a γδ-driven T cell lymphoma (n = 68). x axis indicates amino acid position of each mutation. y axis indicates number of 
patients with the same mutation. Circles are color coded by type of mutation (pink, in-frame indel; purple, missense SNV; green, frameshift indel; orange, 
nonsense SNV). Colored regions in protein diagram represent protein domains (lime green, AWS [associated with SET] domain; blue, SET domain; red, 
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tissue (Peyer’s patches) from these mice and evaluating T 
cell markers by flow cytometry. The flow cytometry gating 
schemes for analysis and sorting are shown in Fig. S2 (a–g) 
for IELs. In IELs from Setd2 wild type mice, CD3epos T cells 
ranged from 40% to 80% of the live cells within the lympho-
cyte gate. Typically, TCRγδpos were ∼1.3 times more prevalent 
than TCRβpos cells and 90% of both subsets were CD8αpos. In 
Peyer’s patches from Setd2 wild-type mice, CD3epos T cells 
were ∼25% of the live cells within the lymphocyte gate with 
TCRβpos outnumbering TCRγδpos cells ∼20 to 1. Although 
<25% of the TCRβpos cells were CD8αpos, the majority (60%) 
of TCRγδpos cells were CD8αpos.
We compared the proportion of IEL T cells that are 
CD3epos and TCRγδpos versus CD3epos and TCRβpos in the 
Setd2 wild-type and deficient mice (Fig. 3 e) and found a sig-
nificant increase in the γδ-positive T cell population (ANO 
VA F-test, P = 0.035), and a commensurate decrease in the 
αβ T cell population (ANO VA F-test, P = 0.002), resulting 
in an increase in the ratio of γδ T cells to αβ T cells from 
1.4 to 2.2 (ANO VA F-test, P = 0.001). Fig. 3 f shows repre-
sentative flow cytometry plots from Setd2+/+ and Setd2−/− T 
cells, which show the shift toward a higher γδ T cell pop-
ulation in the Setd2 knockout. An increase in the ratio of 
TCRγδpos to TCRβpos T cells was also evident in Peyer’s patch 
T cells (Fig. S2, h–l).
To further investigate the phenotype of SETD2 loss 
in IELs, we profiled the gene expression of αβ and γδ 
sorted IELs, isolated from Setd2+/+ and Setd2−/− T cells. 
Fig. S3 a shows the confirmation of the expected deletion 
of exon 2 of Setd2 from the RNA-sequencing data. Some 
of the most highly expressed genes in the IELs included 
Gzma, Gzmb, Ccl5, Txndr1, Rgs1, and B2m (Table S7). We 
identified the top differentially expressed genes between 
the αβ and γδ T cells, which included known T cell marker 
genes such as Cd4, Cd8b1, Icos, and Cd28 as more highly 
expressed in αβ T cells, and Ctsh, Tgm2, and Ctsh as more 
highly expressed in γδ T cells (Fig. S3 b). Genes that differ-
entiated Setd2−/− and Setd2+/+ IELs included Lst1, Tcea2, 
Bmp7, Klk1, Agr2, and Msrb1 (Fig. S3 c). Interestingly, we 
found that overall, the genes that had higher gene expres-
sion in γδ T cells (fold change >2 compared with αβ T 
cells), were highly enriched among the genes that increase 
in the Setd2 knockout (Fig. S3, d and e), supporting the 
notion that Setd2 loss may favor the development of T 
cells with a γδ-like phenotype.
No significant difference was found between the two 
genotypes in overall proportions of CD3epos or the propor-
tion of the TCRβpos or TCRγδpos that are CD8αpos. Table S8 
lists the cell counts and proportions from IELs and Peyer’s 
patches for αβ and γδ T cell populations, as well as a sum-
mary of the results for CD3e and CD8α. Setd2 deficient mice 
did not thus far develop lymphoma at up to 10 mo of age, 
suggesting that additional collaborating genetic events are 
needed for oncogenic transformation.
Collectively, these data point to a novel role for SETD2 
in T cell development and suggest that SETD2 loss may favor 
the development of γδ T cells.
dIScuSSIon
EATL is an uncommon but lethal disease. In this study, we 
have assembled one of the largest cohorts of patients with 
EATL to define the genetic underpinnings of the disease. Our 
work defines many previously unknown mutational drivers 
of the disease, including chromatin modifiers, DNA damage–
related genes, and activated signaling pathways. Our results 
show that SETD2 is the most frequently silenced gene in 
this disease, revealing the importance of loss of function of 
SETD2, as well as other epigenetic modifiers in general in the 
oncogenesis of EATL. Our data also suggest the JAK-STAT 
signaling pathway as an immediate therapeutic target in the 
disease, with over half of the EATL patients manifesting mu-
tations in this pathway.
post-SET domain; pink, low-charge region; dark green, WW domain; yellow, SRI [Set2 Rpbl-interacting] domain). (Bottom) Conservation of SET (blue) and 
SRI (yellow) domain amino acid sequences. Nonconserved amino acids are colored in red. (b) Setd2 expression during T cell development. Labeled circles 
indicate different stages of T cell development. Corresponding scatterplot shows mouse gene expression (fourfold range) during development, with circles 
colored by expression. Values represent mean expression from two to three samples per group (34 total samples). αβ T cells differentiate from the DP early 
T cells, whereas γδ T cell differentiate from the DN3 stage of early T cell. Stages: early T precursor (ETP), DN2A, DN2B, DN3A, DN3B, DN4, immature single 
positive (Imm. SP), DP CD69− (DP 69−), DP CD69+ (DP 69+), γδ T cell (γδ), αβ CD4+ T cell (αβ 4+), αβ CD8+ T cell (αβ 8+). (c) Mouse breeding diagram. The final 
cross is between a heterozygous knockout Setd2+/fl mouse and a heterozygous knockout Setd2+/fl mouse with Cre transgene under the control of the T cell–
specific Lck promoter (Lck-Cre+). The progeny mice that are used for downstream experiments are the wild-type Setd2 (+/+, blue) and null Setd2 (−/− in T 
cells, red), both with one copy of the Lck-Cre transgene. (d) Western blot in CD3+ splenic T cells from the Setd2 wild-type mouse (left) and Setd2-null mouse 
(right). (Top) SETD2 protein, (middle) H3K36 trimethylation, (bottom) β-tubulin control. Blot is representative of three experimental replicates. (e) Bar graph 
showing the quantification of CD3epos and TCRγδpos or CD3epos and TCRβpos T cell populations within IELs. Blue bars show populations from the Setd2+/+ 
wild-type T cells. Red bars show populations from the Setd2−/− null T cells. (Left) Left bars show γδ T cell receptor expressing populations, and right bars 
show αβ T cell receptor expressing populations. (Right) Ratio of γδ T cells to αβ T cells in Setd2+/+ T cells versus Setd2−/− T cells. Error bars show standard 
error of the mean. Two-way ANO VA tests were done for comparisons across genotype, correcting also for experimental batch. P-values for genotype dif-
ferences are 0.035 (γδ T cells), 0.002 (αβ T cells), and 0.001 (ratio of γδ T cells to αβ T cells). Data are shown from five different experimental batches with a 
mean of five mice per batch. Total number of Setd2 wild-type mice: 11. Total number of Setd2-null mice: 15. (f) Flow cytometry representative plot showing 
the proportion of cells with TCR γδ and TCR β staining, corresponding to the αβ and γδ TCR-expressing T cell populations. (Left) Setd2 wild-type mouse 
(+/+). (Right) Setd2-null mouse (−/−). Plots are representative of results found comparing 11 Setd2 wild-type mice and 15 Setd2-null mice.
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The classification and naming of EATL and its subtypes 
have been debated extensively (Chan et al., 2011; Tse et al., 
2012; Nairismägi et al., 2016; Roberti et al., 2016). The clas-
sification schemes developed thus far largely rely on mor-
phological distinctions and limited immunophenotyping and 
copy-number data. Next-generation sequencing provides a 
powerful tool for systematically defining the genetic differ-
ences between the subtypes. Interestingly, we observed that 
the types of EATL demonstrate highly convergent genetics 
in the face of divergent gene expression. These findings sug-
gest that the two subtypes of EATL have potentially different 
cellular phenotypes that nevertheless follow similar genetic 
pathways to the development of EATL.
Knowing when to reclassify a disease is difficult, partic-
ularly in a rare entity such as EATL. There are many potential 
benefits of increasing the resolution of diagnosis, including 
the ability to define the basis of distinct clinical outcomes, 
as well as the ability to identify distinct aspects of biology. 
However, such fragmentation of the disease landscape can also 
pose challenges in trying to perform clinical trials and trying 
to improve clinical outcomes, particularly in uncommon dis-
eases such as EATL, where the described subtypes have similar 
outcomes and distribution of therapeutically targetable mu-
tations. DNA and RNA sequencing provides the basis for a 
data-driven approach to disease classification. It appears inev-
itable that such data will inform future classification schemes.
SETD2 is the most frequently silenced gene in EATL. 
T cell development involves the concerted action of many 
different genes at well-defined stages of development. Expres-
sion analysis in mouse data indicates that Setd2 is selectively 
down-regulated in the steps that are critical precursors of γδ 
T cells and an up-regulation of Setd2 is a feature of precur-
sors of αβ T cells. SETD2 loss in mice is associated with an 
expansion of γδ T cells, suggesting a novel role for SETD2 in 
T cell development, in addition to its other described roles in 
oncogenesis (Dalgliesh et al., 2010; Zhu et al., 2014). Inter-
estingly, a known hallmark of celiac disease is an increase in 
the proportion of γδ T cells (Kagnoff, 1998). The lack of lym-
phoma development in Setd2 knockout mice suggests that 
the development of EATL requires the activation of other 
collaborating genetic events. More work is needed to fully 
define the role of SETD2 in the oncogenesis of EATL and 
other peripheral T cell lymphomas, such as HSTL, where it 
is also highly mutated.
This work defines the complete mutational, co-
py-number, and transcriptomic landscape of EATL genetics 
in one of the largest studies in this disease to date. Our in vivo 
experiments support a role for SETD2 loss in T cell develop-
ment and lay the groundwork for future investigation into the 
role of this driver gene in T cell lymphomas.
MAtErIALS And MEtHodS
Study design and sample selection
EATL tumors and normal tissues were obtained from institu-
tions that constitute the Hematologic Malignancies Research 
Consortium (Jima et al., 2010). Tumor samples were derived 
from FFPE tissues, and normal samples were from unaffected 
bone marrow, when available. Archival patient tumor and 
normal samples, as well as clinical data, were collected ac-
cording to a protocol approved by the Duke University In-
stitutional Review Board, which was exempt from informed 
consent, and in accordance with the Declaration of Helsinki.
Exome sequencing and derivation of genomic data
In brief, genomic DNA was sheared to 250 bp and size/con-
centration were verified using Bioanalyzer (Agilent Technol-
ogies). Sheared DNA was end-repaired, A-tailed, and ligated 
to Illumina paired-end adapters. The resulting libraries were 
amplified using Illumina PE specific primers. Samples were 
column purified and the size and quantity of the final librar-
ies was determined using Bioanalyzer. The resulting libraries 
were then hybridized overnight to DNA baits provided in the 
SureSelect Human All Exon 50 MB kit (Agilent Technolo-
gies). The captured libraries were amplified and sequenced on 
Illumina Hiseq (Table S9).
rnA-sequencing library preparation for tumors
RNA was extracted and assessed for quality using the Bioana-
lyzer RNA Pico chip. Ribosomal RNA (rRNA) was depleted 
using a custom RNaseH method similar to other published 
methods (Morlan et al., 2012; Adiconis et al., 2013). 1 µg total 
RNA was hybridized with 1 µg of a custom DNA oligo mix 
tiling the 18s, 28s, 5.8s and mitochondrial rRNA sequences 
(Table S10). Each sample was then RNaseH treated to de-
grade complementary rRNA sequence and DNase treated to 
degrade the DNA oligo mix. The remaining rRNA-depleted 
samples were then purified using the RNeasy Mini kit as 
directed (QIA GEN). The Kapa Stranded RNA-Seq kit was 
used to generate stranded Illumina sequencing libraries (Kapa 
Biosystems). In brief, RNA was hybridized to random prim-
ers, followed by first-strand cDNA synthesis, second-strand 
cDNA synthesis with marking, A-tailing, ligation of Illumina 
paired-end adapters with 8-bp barcodes, and nine cycles of 
PCR amplification. Reactions were purified with Agencourt 
AMPure XP beads where necessary. Paired-end, library- 
prepared RNA was captured using SureSelect Exome 
V6+UTR capture baits from Agilent Technologies (Cieslik et 
al., 2015). The quality and quantity of the final captured libraries 
were assessed using the Bioanalyzer. Libraries were multiplexed 
in equimolar amounts and sequenced as paired-end 50-bp 
(100-bp) reads on an Illumina HiSeq Sequencing System.
Exome sequencing alignment
Reads in FAS TQ format (Cock et al., 2010) were preprocessed 
with GATK (McKenna et al., 2010) version 3.2–2 to remove 
Illumina adapter sequences (analysis type –T ClipReads, -XF 
illumina.adapters.fa) and Phred-scaled base qualities of 10 
and below (−QT 10) as described previously (Love et al., 
2012; Zhang et al., 2013, 2014). After GATK processing, reads 
were mapped to the hg19 reference genome using Burrows–
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Wheeler Aligner version 0.7.7 (BWA mem –M –p; Li and 
Durbin, 2010). Output was converted to BAM format with 
SAMtools (Li et al., 2009) version 0.1.19. All alignments were 
output as BAM files and merged using Picard version 1.96 
(http ://picard .sourceforge .net). PCR/optical duplicates were 
marked by Picard. Base quality recalibration was performed 
using GATK to generate a more accurate base quality score 
that takes into account its reported quality score in the original 
FAS TQ file, position within the read, and sequence context, 
for example AC and TG dinucleotides. To improve accuracy 
and quality of alignment, localized indel realignments were 
performed using GATK, which infers the consensus indel 
call from multiple reads mapping to suspected indel genomic 
regions, rather than considering each read independently. 
Regions that should be realigned are determined by the 
GATK Realigner Target Creator.
Variant calling and annotation
SAMtools (Li et al., 2009) mpileup with settings “-C50 -m3 
-F0.0002” was run on all cases and output to a single VCF 
file. The mpileup settings do the following: “-C50” limits the 
contribution of reads with many mismatches, and “-m3 –
F0.0002” is used to maximize sensitivity to indel discovery by 
requiring three supporting reads at a minimum of 0.02% abun-
dance, rather than the default abundance cutoff of 0.2%. Each 
variant was required to have an instance of genotype quality 
>30 and read depth >5. For all samples for which paired nor-
mal DNA was available, MuTect version 1.1.7 (Cibulskis et 
al., 2013) was used to detect truly somatic variants, which 
are absent in the normal germline DNA (tumor LOD score 
cutoff set to 4.5 for increased sensitivity). MuTect was also 
run on all human tumor exome samples to take advantage of 
the increased sensitivity for low allelic fraction variants. Mu-
Tect called variants were merged with mpileup variants for 
downstream processing. Individual single nucleotide variants 
(SNVs) and indels from human exomes were annotated with 
gene names, predicted function, population frequencies, and 
other variant annotations using Annovar (Wang et al., 2010), 
which takes as input genomic coordinates and variants, and 
outputs alteration (amino acid change, frameshift, stop gained, 
etc.), scores from various predictors, including SIFT (Sim et 
al., 2012), Polyphen-2 (Adzhubei et al., 2013), and CADD 
(Kircher et al., 2014), as well as any observed frequencies in 
the NHL BI 6500 Exomes Sequencing Project and dbSNP.
Variant filtering and the identification of EAtL driver genes
The first round of variant filtering required variants to be 
absent from control populations (NHL BI 6500 Exomes 
Sequencing Project, in-house normal exomes, and EATL 
paired normals). We also required variants to have a frequency 
within the EATL dataset <30% for SNVs and <5% for in-
dels (to eliminate obvious alignment artifacts) and to not 
have missing data in >50% of the samples. Highly recurrent 
SNVs required outside support from COS MIC and/or the 
literature. Furthermore, variants were filtered out that lie in 
genomic regions with high duplication scores. Finally, the 
variant had to have an alternate allele read depth of at least 
3, total read depth of at least 5, and an allele frequency of at 
least 5% in one sample. Next, we formed our discovery gene 
set using all genes implicated with at least two somatic events 
in our paired cases, as shown in the separation of discovery 
and validation sets in Fig. 1. Within these genes, we required 
these genes to be expressed in T cells (FPKM >1) and to not 
be overly variable in the normal population (restrictions on 
number of variants in the 6500 exome project and number of 
variants over gene size). Most importantly, to identify EATL 
driver genes, we required genes to have at least 3 not-synon-
ymous events across at least 4 cases out of the highly filtered 
variants. Additional steps to identify drivers involved requir-
ing a high proportion of identified variants in a gene to have 
high CADD scores and be completely absent in population 
databases and for the gene to have a high ratio of not-synon-
ymous to synonymous events.
Mutual exclusion testing
Mutations in final driver gene list (excluding synonymous) 
were tested for mutual exclusion using the weighted row ex-
clusivity test, using the Saddlepoint approximation for p-value 
(Leiserson et al., 2016). Sets of three and four genes were 
tested for mutual exclusion. Within the significant sets of four 
genes, the presence of all gene pairs in these sets was counted.
Arm-level copy-number calling
Copy numbers from exome sequencing data were generated 
using the EXC AVA TOR (Magi et al., 2013) tool, in both 
the pooled and somatic mode. All tumor samples were run in 
pooled mode, against a pool of EATL normal samples, thus 
controlling for any population variation, and artifacts were 
generated in the exome sequencing process. Reported alter-
ations were confirmed to occur somatically in the paired sam-
ples, via the paired mode of EXC AVA TOR. Normals were also 
run against other normals to confirm no significant alterations 
in the paired normal samples and control for any remaining ar-
tifacts. This program evaluates read depths at each exon, based 
on the exome capture bait BED file, and normalizes based on 
the paired or pooled normals provided. Smoothing of the ex-
on-level data provides the copy-number segmentation. Next, 
the program output was input into GIS TIC 2.0 (Mermel et 
al., 2011) to determine significant arm-level copy-number 
changes in the EATL dataset. Significant arm level alterations 
in the EATL tumors from GIS TIC were selected for further 
investigation and filtered against any alterations that were re-
turned as significant in the normal dataset. Furthermore, to 
call sample-level arm-level amplification and deletions, we re-
turned to the EXC AVA TOR data and performed a rank-sum 
test between the exon level data of each arm of each sample 
against data from all other arms in that sample. To call a sample 
altered in that chromosome arm, we required that this test 
had a significant p-value (<0.01) after correcting for multiple 
testing with a Bonferroni correction, as well as a significant 
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increase/decrease in the tumor/normal ratio, equivalent to one 
copy gained or lost in a 10% pure tumor, as the minimum. 
Again, arms that are significant in any of the normal samples 
are removed. GIS TIC runs were repeated with only type I or 
only type II samples separately, and alterations with significant 
q-values in those runs were also included.
Allele frequency and cancer cell fraction analysis
Purity estimates are taken as the maximum of the copy num-
ber based estimate from the driver copy-number alterations 
reported and the mutation allele frequency based estimate 
from the driver gene mutations reported. Allele frequencies 
are corrected for purity and assumed to be from heterozygous 
mutations to calculate cancer cell fraction. Only mutations 
with at least five reads are included in the analysis.
HLA genotyping
HLA genotyping was performed using EATL tumor and nor-
mal exome sequencing FAS TQs and the PHL AT algorithm 
(Bai et al., 2014). The PHL AT python package was run using 
Python 2.7 and Bowtie2 (2.1.0). When possible, tumor and 
normal FAS TQs were merged for analysis because the HLA 
genotype that we are interested in is the germline genotype. 
Tumor and normals were also assessed separately and were 
found to have a high degree of concordance. Table S4 shows 
the genotypes for DQA1 and DQB1, the two genes most rel-
evant for establishing the celiac disease-associated HLA type, 
as well as the serotype groups for DQA1 and DQB1.
rnA-sequencing alignment and expression quantification
RNA-sequencing reads were first trimmed for removal of 
adapter sequences and low-quality bases with Trimmomatic 
(Bolger et al., 2014; version 0.32; adapters: 2:20:7:1:true, lead-
ing: 5, trailing: 5, slidingwindow: 4:10, minlen: 21). Next reads 
were aligned with Bowtie2 (Langmead and Salzberg, 2012; 
version 2.1.0, with local alignment) against a custom rRNA 
reference built by searching the NCBI nucleotide database for 
Homo sapiens rRNA, rRNA molecule type (or Mus muscu-
lus). Remaining reads were aligned with Tophat (Trapnell et 
al., 2012; version 2.0.9) to the hg19 transcriptome (Ensembl 
v74), with remaining reads aligned to the hg19 genome (or 
mm10 equivalents for mouse data). Expression quantifica-
tion was done using Cuffquant and Cuffnorm (Trapnell et 
al., 2012; version 2.2.0, cuffquant –u –b). FPKM values from 
Cuffnorm were used in downstream analysis.
differential expression and gene set enrichment analysis
Samples were filtered for quality, and genes that had a 
median expression greater than 0 in the dataset were used for 
further analysis. An additional step of quantile normalization 
was applied to the filtered dataset. Differentially expressed 
genes were identified using Student’s t test and fold change 
(FDR <0.1, fold change > 1.5×). Principal-component 
analysis, volcano plots, and differential expression tests 
were all performed using Matlab (R2016a). Gene set 
enrichment was run as a hypergeometric test comparing 
each gene set to the list of differentially expressed genes 
between type I and type II EATL. The MSigDB Hallmark, 
KEGG, and REA CTO ME gene set lists were used for 
comparison. Ranked list gene set enrichment using GSEA 
(Subramanian et al., 2007) was also run using the same gene 
sets. Enrichment plots across the ranked list are generated 
using the GSEA software and gseapy (http ://pydigger .com 
/pypi /gseapy). FDR correction is done for both differential 
expression and gene set enrichment according to the 
Benjamini–Hochberg method.
comparison of EAtL tumors to t cell subsets
EATL tumor RNA-sequencing samples were compared with 
the T cell subset gene expression data from the Immunolog-
ical Genome Project (Heng et al., 2008). All T cells samples 
available from unmodified C57BL/6 mice were used for 
comparison. Datasets were filtered to common genes. Pearson 
correlations were computed for each EATL tumor against 
each T cell sample. T cell samples are then ranked by mean 
correlation across the EATL tumors.
Statistics
The log-rank test was used to test significance in survival 
associations with clinical covariates. Survival curves were 
drawn using the Kaplan–Meier method. Differentially ex-
pressed genes were selected as those with at least 1.5-fold 
difference between the two groups and an FDR (q-value) 
<0.1 (Benjamini–Hochberg FDR correction after Student’s 
t test.) Principal-component analysis was run using the pca 
command in Matlab R2016a. Gene set enrichment analysis 
was run using the hallmark gene sets from MSigDB, Re-
actome, and KEGG gene sets. A two-way ANO VA model 
was used to compare T cell population percentages between 
wild-type and knockout mice while controlling for ex-
perimental batch effect.
Mouse strains
Mice were housed in a Duke University Medical Center 
Division of Laboratory Animal Resources facility and ex-
periments approved by the Duke University and Medical 
Center Animal Care and Use Committee. The Setd2 con-
ditional knockout mouse line designated C57BL/6N-Set-
d2<tm1c(NCOM)Mfgc>/Tcp was made as part of the 
NorCOMM2 project with C57BL/6NSetd2<tm1a(N-
COM)Mfgc>/Tcp made from NorCOMM ES cells at the 
Toronto Centre for Phenogenomics. The line was made 
available to us through the Canadian Mouse Mutant Re-
pository. The Lck-Cre transgenic strain for T cell–spe-
cific CRE expression was provided by Y. Zhuang (Duke 
University, Durham, NC; Pan et al., 2002). For the eval-
uation of SETD2 function in T cells, Setd2+/fl mice were 
crossed to Setd2+/fl; Lck-Cre+ mice. The progeny of such 
crosses included mice whose T cells were Setd2 wild-
type, heterozygous, or null.
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Mouse genotyping
Genotyping was performed on tail-snip DNA using the QIA 
GEN HotStarTaq master mix. The Setd2 alleles were iden-
tified using primers 5′-TAG CTG TGC TTG AGT TGC CAC 
AGA GC-3′ and 5′-TCC TGA AGC TGG TGC AAA CCA 
CTA GG-3′ and an annealing temperature of 60°C. The wild-
type allele produced a 571-bp product, whereas the floxed 
allele produced a 665-bp product. The Lck-Cre transgene was 
identified using primers 5′-GCA GGA AGT GGG TAA CTA 
GAC TAAC-3′ and 5′-TCT CCC ACC GTC AGT ACG TGA 
GAT ATC-3′ and an annealing temperature of 55°C. Presence 
of the transgene was indicated by a 750-bp product.
Mouse dissection and isolation of lymphocytes
Mouse Peyer’s patches and IELs were harvested in RPMI-
1640 medium containing 10% (vol/vol) FBS. Single-cell 
suspensions of Peyer’s patch lymphocytes were made by 
squeezing dissected Peyer’s patches between ground glass 
slides. IELs were isolated from dissected, washed, and inverted 
small intestinal fragments using a DTT-based extraction me-
dium and sequential filtration steps. The detailed protocol is 
as follows: We modeled our isolation of IELs on the protocol 
by Couter and Surana (2016). Just before mouse dissection, 
IEL extraction media was prepared for each mouse (30 ml 
RPMI supplemented with 60 µl 0.5 M EDTA and 500 µl 
FBS). The extraction medium was placed into a 125-ml plas-
tic culture flask and warmed to 37°C in a tissue culture in-
cubator. Freshly prepared DTT (93 µl 5% wt/vol in dH2O) 
was added immediately to each flask before addition of in-
testinal segments. The mouse was euthanized and an incision 
made to expose the gut contents. The small intestine was sep-
arated from the stomach by transection of the pyloric sphinc-
ter with scissors. The small intestine was removed from the 
peritoneum and mesenteric fat teased away. A second cut was 
made at the ileocecal junction. The isolated small intestine 
was rinsed and stored when not being manipulated in ice-
cold RPMI/10% FBS to maximize cell viability. The small 
intestine was manipulated on paper towels moistened with 
RPMI/10% FBS. All the Peyer’s patches were excised from 
the surface of the small intestine, placed in cold RPMI/10% 
FBS, and a single-cell suspension made by squeezing the tis-
sue between ground glass slides (Micro Slides; Corning) and 
filtering the suspension through 70 µm cell strainers (Falcon). 
Red blood cells were lysed and remaining Peyer’s patch cells 
were washed twice with PBS/2% FBS before flow cytom-
etry. Upon removal of Peyer’s patches, the central third of 
the small intestine was selected to be the source of IELs and 
remaining fat thoroughly and gently removed using curved 
forceps. The intestinal segment was then subdivided into 
three or four 1.5–2-in segments. Intestinal contents were re-
moved by gently flushing the segments with 15–20 ml cold 
PBS using a butterfly needle affixed to a syringe. Each seg-
ment was inverted by cannulating the segment with curved 
forceps, grasping the distal end of the tissue, using a needle 
to pass the end of gut into the forceps and finally pulling the 
forceps back out to invert the segment of gut. The segments 
were rinsed and stored in cold RPMI/10% FBS before being 
transferred into the culture flasks with prewarmed extraction 
medium. The flasks were shaken at 400 rpm for 15 min at 
37°C. After incubation, a steel tea strainer was used to separate 
tissue pieces from the IELs contained in the cloudy filtrate. 
The filtrate was then put through a 100-µm cell strainer into 
a 50-ml conical tube, and for better recovery, the filter was 
rinsed with 20 ml RPMI/10% FBS. The solution was centri-
fuged at 500 g for 10 min at 4°C. The supernate was carefully 
decanted, and the pellet resuspended in 5 ml RPMI contain-
ing 10% FBS. The resuspended cells were filtered through a 
40-µm filter, the filter rinsed with 15 ml RPMI/10% FBS, 
and the filtrate centrifuged again at 500 g for 10 min at 4°C. 
The supernate was carefully decanted and the pellet resus-
pended in 5 ml RPMI containing 10% FBS. The IELs were 
counted in Trypan blue with a yield of 15–50 million cells/
animal with ∼70% viability.
Western blotting
Mouse splenic CD3pos T cells were isolated by filtering sus-
pended spleen cells through a 70-µM cell strainer, exposed 
to RBC lysis buffer, and washed twice with PBS with 0.5% 
BSA. CD3e+ spleen T cells were then positively selected for 
by cell surface staining with CD3e PE-Cy5.5 antibodies and 
MACs microbeads passed through LS columns (Miltenyi 
Biotech) according to the manufacturer’s protocols. For each 
sample, 5 × 106 cells were washed once in ice cold PBS and 
lysed in 150 microliters RIPA buffer (Sigma-Aldrich) with 
protease, phosphatase inhibitors (Roche), and 2 mM EDTA. 
Crude lysates were sonicated at 10% duty cycle, intensity 4, 
200 cycles/burst on a Covaris S-series device then centri-
fuged at 13,000 g for 10 min, and supernatants were used for 
downstream experiments. 10–30 µg of protein were separated 
on 4–18% Bis-Tris gradient gels and transferred overnight 
to Immobilion PVDF membranes (EMD Millipore) in Tris- 
glycine buffer with 20% methanol at 30 V. Primary antibodies 
(anti-SETD2, anti-H3K36me3, and anti–β tubulin; Cell Sig-
naling Technology) were diluted 1:1,000 in 5% BSA/TBS-T 
and bound overnight followed by washing and binding of 
HRP-conjugated anti–rabbit antibody (Santa Cruz Biotech-
nology, Inc.). Blots were developed using SuperSignal Pico 
chemiluminescent substrate (Thermo Fisher Scientific).
Flow cytometry
For the analysis of T cell populations, IEL preparations, and 
Peyer’s patch cells were blocked using CD16/32 then incu-
bated with antibodies to surface antigens for 20 min at 4°C. 
Cells were washed twice, resuspended in PBS/2% FBS, and 
analyzed by flow cytometry using a Sony LE-SH800 flow cy-
tometer and cell sorter. Identification of TCR γδpos and TCR 
βpos cells was based on the staining and gating strategy illus-
trated in Fig. S2. Cells are within the lymphocyte gate, singlets, 
viable, and CD3eposTCRγδpos or CD3eposTCRβpos. Antibod-
ies used in this study included BV421-conjugated anti-CD3e 
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(145-2C11; BioLegend), PE-conjugated anti-CD8a (53-6.7; 
BD Biosciences), APC-conjugated anti-TCR β (H57-597; 
BioLegend), and PE/Cy7 anti-TCR γδ (GL3; BioLegend) 
with Zombie Green (BioLegend) used to identify viable cells.
Flow cytometry analysis
Flow data from Peyer’s patch samples were collected from 
nine experiments, and flow data from IEL preparation samples 
were collected from five experiments. Samples for each tissue 
were combined for analysis in FlowJo to standardize the gates. 
In the case of the Peyer’s patches, samples were excluded if 
less than 70% of the total cells in the forward versus side scat-
ter plot fell within the lymphocyte gate; this was to prevent 
incorporation of samples with significant IEL contamination 
caused by the incorporation of excessive gut wall tissue in the 
dissection. In the case of IEL preparations, samples were ex-
cluded if less than 5% of total cells in the forward versus side 
scatter plot fell within the lymphocyte gate; this effectively 
excluded samples with poor retrieval of viable lymphocytes.
rnA-sequencing library preparation for IELs
αβ and γδ IELs were isolated from the intestinal epithelium by 
sorting during flow cytometry as described. The purified IELs 
were then pelleted and lysed using RNA Lysis Buffer (Zymo). 
Total RNA was isolated using the Zymo Quick-RNA Mi-
croPrep kit per manufacturer’s instructions. RNA sequenc-
ing libraries were then created using the KAPA Stranded 
mRNA-Seq kit (Kapa Biosystems). In brief, mRNA was se-
lected with poly-T beads, mRNA was fragmented and hy-
bridized to random primers, followed by first-strand cDNA 
synthesis, second-strand cDNA synthesis with marking, 
A-tailing, ligation of Illumina paired-end adapters with 8-bp 
barcodes, and 12 cycles of PCR amplification. Reactions were 
purified with Agencourt AMPure XP beads where necessary. 
Samples were then sequenced as paired-end 75-bp (150-bp) 
libraries on the Illumina MiSeq Sequencing System.
data availability
Primary sequence data are available at the European Genome- 
phenome Archive under accession no. EGAS00001001954.
online supplemental material
Fig. S1 shows mutually exclusive gene sets, cancer cell fraction 
for driver genes, and exploratory Kaplan-Meier plots for clin-
ical and molecular covariates (related to Fig. 1). Fig. S2 shows 
the flow cytometry scheme for sorting and quantifying T cell 
populations from the Setd2 wild-type and knockout mice in 
IELs and the proportions of T cells in Setd2 wild-type and 
knockout mice for Peyer’s patches (related to Fig. 3). Fig. S3 
shows the RNA-sequencing analysis of IELs (related to Fig. 3). 
Tables S1–S10 are available as tabs in an Excel file. Table S1 lists 
the variants in EATL significantly mutated genes. Table S2 lists 
the mutual exclusion sets. Table S3 lists the copy-number alter-
ations in EATL. Table S4 lists the HLA genotypes for DQA1 
and DQB1 genes. Table S5 lists the clinical and pathological 
features of the EATL cases. Table S6 lists the differentially ex-
pressed genes between type I and type II. Table S7 lists the RNA 
sequencing gene expression for the IELs. Table S8 lists the in-
dividual T cell proportions for IELs and Peyer’s patches. Table 
S9 lists the summary statistics for exome and RNA sequencing. 
Table S10 lists the oligo sequences used for rRNA depletion.
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